Found 17 results
Author [ Keyword(Asc)] Title Type Year
Filters: Author is Metz, Thomas O  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
RNA, Ribosomal, 16S
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Randomized Controlled Trials as Topic
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Propiophenones
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Prebiotics
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Microbiota
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Inflammation
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Humans
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Gastrointestinal Microbiome
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Flavonoids
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Crohn Disease
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Clinical Trials, Phase II as Topic
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Biomarkers
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Biological Products
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.
Adult
Jamieson PE, Smart EB, Bouranis JA, Choi J, Danczak RE, Wong CP, Paraiso IL, Maier CS, Ho E, Sharpton TJ et al..  2024.  Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.. Gut Microbes. 16(1):2315633.
Langley BO, Ryan JJoan, Phipps J, Buttolph L, Bray B, Aslan JE, Metz TO, Stevens JF, Bradley R.  2022.  Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.. Trials. 23(1):885.